IP Library › Granted Patent US 10,221,133
Granted Patent B2
US 10,221,133 · App. 15/545,966 · Granted Mar 5, 2019

(Thio, oxo, and seleno) semicarbazone complexes with zinc and their use for treating cancer

Inventors: David J. Augeri (New Brunswick, NJ); Anthony F. Bencivenga (New Brunswick, NJ); Adam Blanden (Syracuse, NY); Darren R. Carpizo (New Brunswick, NJ); John A. Gilleran (New Brunswick, NJ); Spencer David Kimball (New Brunswick, NJ); Stewart N. Loh (Syracuse, NY); Xin Yu (New Brunswick, NJ)
Assignees: Rutgers, The State University of New Jersey; The Research Foundation for the State University of New York
C07C337/08A61K31/175A61K31/315A61K31/397C07C281/08C07D205/04C07D213/53C07D401/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,221,133
App. No.
15/545,966
Granted
Mar 5, 2019
Kind
B2
Abstract

The invention provides organic complexes of Zn 2+ of formula (I) that are useful for treating cancer, as well as compositions and kits comprising such complexes, and intermediate monomer compounds that are useful for the preparation of such complexes.

Claims (27)

1. A complex comprising Zn 2+ and a compound of formula (I):

or an ion or poly-ion thereof, wherein:

n is 0, 1, 2, 3, or 4;

Y is O, S, or Se;

each R 1 is independently selected from (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, hydroxyl, and halo;

R 2 is selected from the group consisting of H and (C 1 -C 6 )alkyl that is optionally substituted with aryl; and

R a and R b taken together with the nitrogen to which they are attached form a 4-, 5-, or 6-membered heterocycle that is optionally substituted with one to three substituents independently selected from (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, hydroxyl, halo, aryl, and heteroaryl;

or a solvate thereof.

2. The complex of claim 1 wherein:

n is 0;

R 2 is (C 1 -C 4 )alkyl;

Y is S or Se; and

R a and each R b taken together with the nitrogen to which they are attached form a heterocycle selected from:

or a solvate thereof.

3. The complex of claim 1 that comprises a compound selected from the group consisting of:

and ions and poly-ions thereof or a solvate thereof.

4. The complex of claim 1 wherein the ratio of the number of compounds of formula (I) or ions or poly-ions thereof to zinc Zn′ ions is about 2:1; or a solvate thereof.

5. The complex of claim 4 that comprises a compound selected from the group consisting of:

and ions and poly-ions thereof, wherein: the ratio of the compound or ion or poly-ion to Zn 2+ is about 2:1; or a solvate thereof.

6. A neutral coordination complex comprising Zn 2+ and a compound selected from the group consisting of:

and ions and poly-ions thereof, wherein: the ratio of the compound or ion or poly-ion to Zn 2+ is about 2:1; or a solvate thereof.

7. The complex:

or a solvate thereof.

8. A pharmaceutical composition, comprising a complex of claim 1 or a solvate thereof, and a pharmaceutically acceptable carrier.

9. An injectable pharmaceutical formulation comprising, a complex of claim 1 or a solvate thereof, and a pharmaceutically acceptable carrier.

10. A pharmaceutical composition, comprising a complex of claim 6 or a solvate thereof, and a pharmaceutically acceptable carrier.

11. A pharmaceutical composition, comprising a complex of claim 7 or a solvate thereof, and a pharmaceutically acceptable carrier.

Continuity (3)
Provisional Application 62108415 · Jan 27, 2015
Provisional Application 62258177 · Nov 20, 2015
Related Publication 20180002279A1 · Jan 4, 2018
Cited By (3)
US 12,280,065 US 12,344,626 US 12,734,240